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Abstract: Background/Objective: Recent literature has identified links between vitamin B12 deficiency and depression.We compared the clinical response of SSRI-monotherapy with that of B12-augmentation in a sample of depressed
patients with low normal B12 levels who responded inadequately to the first trial with the SSRIs.
Methods: Patients with depression and low normal B12 levels were randomized to a control arm (antidepressant only) or
treatment arm (antidepressants and injectable vitamin B12 supplementation).
Results: A total of 199 depressed patients were screened. Out of 73 patients with low normal B12 levels 34 (47%) were
randomized to the treatment group while 39 (53%) were randomized to the control arm. At three months follow up 100%
of the treatment group showed at least a 20% reduction in HAM-D score, while only 69% in the control arm showed at
least a 20% reduction in HAM-D score (p<0.001). The findings remained significant after adjusting for baseline HAM-D
score (p=0.001).
Conclusion: Vitamin B12 supplementation with antidepressants significantly improved depressive symptoms in our cohort.
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INTRODUCTION
Major Depressive Disorder is an important global public
health problem associated with the significant burden and is
projected to be the second leading cause of disability by
2020 [1]. Prevalence figures worldwide range between 4.2 –
17% and a systematic review of studies from Pakistan gave
the estimates as high as 34% for anxiety and depressive disorders [2]. Clinical guidelines recommend the use of SSRIs
as first-line treatment [3]. Remission rates in the acute phase
of treatment are 30-40% and an overall 30% show poor response to anti-depressant monotherapy [4-6]. In such cases,
addressing other co-morbid conditions is suggested in addition to upgrading or augmenting anti-depressant doses [3].
Pakistan, a developing country of 17 million people, is
fraught with poverty, inadequate nutrition and underprivileged health systems. Several small-case studies from Pakistan show vitamin deficiencies to be common [7,8]. A small
study from Islamabad on a clinical population of patients
with megaloblastic anemia reported figures of 76% with vitamin B12 deficiency [9]. Although no large scale studies on
general population are available here, studies from neigh*Address correspondence to these authors at the Department of Medicine/
Neurology, The Aga Khan University, Stadium Road, Karachi 74800,
Pakistan; Tel: (9221) 4930051; Ext: 4665, 4681; Fax: (9221) 4934294;
E-mail: mohammad.wasay@aku.edu; mohammadwasay@hotmail.com

1874-205X/13

boring countries that share the culture and climate show vitamin deficiencies to be common [10-12]. A study on a
healthy Indian population showed the prevalence of B12
deficiency to be 47% [13].
Vitamin B12 plays an important role in DNA synthesis
and neurological function. Its deficiency is associated with
hematological, neurological and psychiatric manifestations
of which the latter includes irritability, personality change,
depression, dementia and rarely, psychosis [14]. Recent literature has identified the links between this vitamin deficiency and depression. High B12 levels in serum are associated with good treatment response, high homocysteine levels
which are common in folate / B12 deficiency and in those
suffering from depression are associated with poor response
to anti depressant treatment [15-17]. Hyperhomocysteinemia
may have direct effects on neurotransmitters implicated in
depression [18].
Randomized trials have shown that folate and other nutritional supplementations have a significant effect in treating
the treatment-resistant depression [19,20]. Folate deficiency
has also been linked with the delay in treatment response as
well as relapse [21,22].
To date no adequately designed trial compares antidepressant monotherapy with B12 augmentation. We aimed
to compare the clinical response of antidepressants mono2013 Bentham Open
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therapy with that of B12-augmentation in a sample of depressed patients with low normalB12 levels (190 pg/ml to
300 pg/ml).
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was recorded during 12 weeks by a research officer who was
unaware of the patient’s randomization.
Statistical Considerations

METHODS
The study was designed as an open label randomized
controlled trial (clinical trials registration number (Clinical
Trials.gov ID NCT00939718). Patients were enrolled from
outpatient clinics of the department of Psychiatry at Aga
Khan University Hospital, Karachi Pakistan from December
2009 - June 2010. Depression was defined as Patients scoring ≥ 16 on the 20-item Hamilton Rating Scale for Depression-Urdu version (HAM-D) [23,24].
Low normal B12 level was defined as B12 level ranging
between 190 and 300 pg/ml. Patients with B12 deficiency
(level below190 pg/ml) were not enrolled due to ethical reasons (patients with established B12 deficiency must be
treated and not subjected to randomization).
Ethics Statement
A study protocol was approved by the Ethics Review
Committee of Aga Khan University hospital. All patients
signed an informed consent form.
Randomization and Masking
Patients with depression and low normal B12 levels were
randomized by a computer program into the control arm (antidepressants only) or treatment arm (antidepressants and
injectable vitamin B12 supplementation). The randomization
was carried out using a Microsoft Excel spreadsheet using
the function “RAND” to generate uniform random numbers.
The randomized assignment was determined by partitioning the range of the random number. Randomization was not
concealed for investigators. Antidepressants that were prescribed included either a tricyclic antidepressant (TCA) with
a dose equivalent of imipramine 100 mg to 250 mg/ day and
the SSRIs dose equivalent of Fluoxetine 20 – 40 mg/day.
Patients with concurrent unstable medical illness, history of
manic episodes or psychotic illness, psychotic symptoms in a
depressive episode, concurrent substance misuse and patients
with suicidal ideation were excluded. Participants in the control arm only received the antidepressants. Those in the
treatment arm received B12 intramuscular injectable as 1000
mcg every week during the 6 weeks in addition to the antidepressants.
Any adverse effects of oral medications and injections
(B12) were monitored and documented on an adverse effects
sheet in the patient folder.
A decline in HAM-D score of 20% or more from the
baseline, indicating an improvement in depression, was defined as the primary outcome. The total change in HAM-D
score from baseline to follow up was defined as a secondary
outcome. Additional secondary outcomes included the follow up HAM-D score and a reduction in HAM-D score of
50`
or more from the baseline. Follow up of the HAM-D score

A total of 248 patients equally allocated to the two
groups provides at least 90 percent power, with a 5 percent
type I error rate, using a two-sided hypothesis test. This calculation assumes an anticipated difference in the response
rate of 20 percent between the two groups with a 30 percent
response rate in the SSRI group and at least a 50 percent
response rate in the combination treatment group. Considering a 15 percent dropout rate in each group, an additional
sample of 44 patients equally divided into the two groups
would be needed to yield a total required sample size of 292
patients. Therefore, the target sample size for each arm was
146.
Descriptive statistics were prepared for all characteristics
including means and standard deviations for continuous
measures and frequencies and percentages for categorical
measures. Chi-square or Fisher’s exact tests were used to
compare categorical baseline characteristics. Two-sample t
tests were used to compare continuous baseline characteristics. Chi-square tests were used to examine the association
between treatment and the 20% and 50% reductions in
HAM-D outcomes. These analyses were extended to logistic
regression to adjust for the baseline HAM-D score. Twosample t tests were used to examine the association between
treatment and the follow up HAM-D score or change in
HAM-D score from baseline to follow up. These analyses
were extended to analysis of covariance to adjust for the
baseline HAM-D score. All hypotheses tests were two-sided
and p-values less than 0.05 were considered statistically significant. Analyses were conducted using SAS Version 9.2
(SAS Institute, Inc., Cary, NC, USA).
Results
A total of 199 depressed patients were screened for the
B12 levels. Vitamin B12 deficiency was present in 44 (22%)
patients; 73 (36%) had low normal B12 levels and 82 (42%)
had normal B12 levels. Patients with low B12 levels were
given the prescriptions for B12 replacement therapy in addition to the antidepressants. These patients were not randomized. Out of 73 patients with low normal B12 levels 34
(47%) were randomized to the treatment group while 39
(53%) were randomized to the control arm. There were no
significant differences between the two groups at baseline
except for the higher depression scores in the treatment
group (Table 1). No adverse effects or complications were
noted in either group. For the primary outcome of 20% reduction in HAM-D score, significantly more subjects from
the treatment group showed a 20% reduction unadjusted for
baseline HAM-D score (100% vs. 69%; p < 0.001). Examining a50% reduction from baseline, this effect remained significant (44% vs. 5%; p < 0.001). We also adjusted the
analyses of reduction for the baseline HAM-D score and our
findings remained significant (Table 2). Additionally, the
change in HAM-D score was significantly greater for the
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Baseline Characteristics Shown as Mean ± Standard Deviation or Frequency (Percent)
Treatment (n=34)

Control (n=39)

p-value

Age, in years

37.68 ± 13.38

36.56 ± 12.28

0.71

Total HAM-D

23.21 ± 5.85

19.38 ± 5.70

0.006

Vitamin B12 level

238.49 ± 33.21

245.16 ± 27.82

0.36

Male

18 (52.9)

20 (51.3)

0.89

Female

16 (47.1)

19 (48.7)

Single never married

9 (26.5)

13 (33.3)

Married

21 (61.8)

21 (53.9)

Divorced/separated/widowed

4 (11.8)

5 (12.8)

Gender

Marital status

treatment group, unadjusted and adjusted for the baseline
HAM-D score (Table 2).
DISCUSSION
Coexistence of depression and vitamin B12 deficiency
are not uncommon. These patients are routinely treated with
SSRI and B12 supplementation, however it is not well established whether the people with low normal B12 and cooccurring depression should also receive B12 supplementation. Our study tried to address this issue. Despite not attaining the targeted sample size, the findings appear significant.
Vitamin B12 deficiency was present in 22% of our depressed
population. This frequency is high in a non-vegetarian, relatively young, middle to upper income population of our patients. A recent study of healthy adults from Karachi showed
a population based prevalence of vitamin B12 deficiency
(less than 200 pg/ml) in 9.74% people [25]. These findings
indicate a substantial co-morbidity of B12 deficiency (22%)
in our depressed patient population.
To our knowledge, this is the first randomized control
trial in Pakistani population which has looked at clinically
depressed patients with low B12 levels. We did not randomize B12 deficient patients due to ethical reasons. Low normal
B12 levels were present in 36% of patients. These patients
are often not treated with B12 supplementation. The findings
of our study clearly indicate that these patients demonstrated
significant improvement with B12 supplementation in addiTable 2.

0.84

tion to SSRI as compared to the control group even after
adjustment for baseline HAM-D score. We think that these
patients represent sub group within the clinically depressed
population and a supplementation with B12 along with the
conventional antidepressants may be a useful strategy in the
treatment of depression in such cases.
We did not give sham injections to the control group. A
placebo response due to injections may be responsible for
the significant improvement in the treatment group. We also
did not look at differences in response at specific doses of
antidepressants nor did we stratify our groups on the basis of
type of antidepressants prescribed. We also could not reach
our sample size because we were not able to get another extension in our grant. Due to financial constraints we were not
able to obtain final B12 levels. These are some of the limitations of our study. However, these findings have important
clinical implications. B12 deficiency and low normal B12
levels are common and may be associated with depression
and the inadequate response to antidepressant treatment in
patients with depression. Vitamin B12 supplementation with
antidepressants has significantly improved depressive symptoms in our group. Larger, multi-center studies are required
to extend and replicate our findings.
CONFLICT OF INTEREST
Authors have no conflicts of interests to declare

Outcomes for Follow Up After 3 Months Shown as Mean ± Standard Deviation or Frequency (Percent)
Treatment (n=34)

Control (n=39)

Unadjusted P-value

Adjusted* P-value

20% reduction in HAM-D score

34 (100)

27 (69.2)

<0.001

0.001

50% reduction in HAM-D score

15 (44.1)

2 (5.1)

<0.001

<0.001

Follow up HAM-D score

12.12 ± 5.12

14.38 ± 4.73

0.053

<0.001

Change in HAM-D score

11.09 ± 4.58

5.00 ± 3.38

<0.001

<0.001
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CONSORT
2010 Flow
Diagram
Enrollment

Assessed for eligibility (n=199)

Excluded (n=126)
 Not meeting inclusion criteria (n=126)
 Declined to participate (n= 0)
 Other reasons (n=0)

Randomized (n=73)

Allocation
Allocated to control group (n=39)
 Received allocated intervention (n= 39)

Allocated to intervention group (n= 34)
 Received allocated intervention (n=34)





Did not receive allocated intervention (n= 0)

Did not receive allocated intervention (give r
(n= 0)

Follow‐Up
Lost to follow-up (give reasons) (n=0)

Lost to follow-up (give reasons) (n= 0)

Discontinued intervention (n=0)

Discontinued intervention (n=0)

Analysis
Analysed (n=39)
 Excluded from analysis (n= 0)

Analysed (n=34)
 Excluded from analysis (n=0)

*Adjusted for baseline difference in HAMD scores in the two groups
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